We've updated our Privacy Policy to make it clearer how we use your personal data.
We use cookies to provide you with a better experience. You can read our Cookie Policy here.
Head and neck cancer sufferers are inherently at risk of refeeding syndrome, which had a prevalence of 9.5% in our series. Our results suggest that site of tumour (but not tumour or nodal staging) is a prognostic indicator for developing refeeding syndrome.
